From Dorm Room to Clinic: Catalyzed by Community Support

**From Dorm Room to Clinic:**

**Catalyzed by Community Support**

---

**NOVEMBER 2013**
First in vitro experiments of AMX0035 begin; Initial focus is AD

**JUNE 2015**
Received a grant from ALS Finding a Cure Foundation and Cure Alzheimer’s Fund

**FEBRUARY 2013**
Justin and Josh cofound Amylyx

**APRIL 2015**
Rudy Tanzi, founding chair of the Amylyx SAB, introduces Josh and Justin to Merit Cudkowicz and Peter Foss, who encourage them to focus their efforts on ALS. NEALS SAB Roundtable takes place at the end of the month

**APRIL 2016**
Received a grant from ALSA and ALS Finding a Cure Foundation

**JULY 2017**
First patient enrolls in the phase 2 CENTAUR clinical trial of AMX0035

**JULY 2016**
Steering Committee formed including patients, caregivers, & KOLs

**APRIL 2019**
First patients are dosed in the phase 2 PEGASUS trial of AMX0035 in Alzheimer disease

**DECEMBER 2019**
Amylyx announces the CENTAUR trial met its primary end point

**APRIL 2020**
Last patient enrolled in PEGASUS trial

**TODAY**
Amylyx is working with regulatory authorities on next steps

**NEALS**
Northeast Amyotrophic Lateral Sclerosis Consortium

---

**FEBRUARY 2013**
Justin Klee and Josh Cohen, 2 undergraduates at Brown University, hypothesize that simultaneously targeting 2 dysfunctional pathways could slow progression in neurodegenerative diseases